Joshua J Solomon1, Scott Matson2, Lindsay B Kelmenson3, Jonathan H Chung4, Stephen B Hobbs5, Ivan O Rosas6, Paul F Dellaripa7, Tracy J Doyle6, Sergio Poli6, Anthony J Esposito6, Ashley Visser3, A Itzam Marin3, Isabelle Amigues8, Evans R Fernández Pérez9, Kevin K Brown9, Michael Mahler10, David Heinz11, Carlyne Cool12, Kevin D Deane3, Jeffrey J Swigris9, M Kristen Demoruelle3. 1. Interstitial Lung Disease Program & Autoimmune Lung Center, National Jewish Health, Denver, CO. Electronic address: solomonj@njhealth.org. 2. Division of Pulmonary and Critical Care Medicine, University of Colorado Denver, Aurora, CO. 3. Division of Rheumatology, University of Colorado Denver, Aurora, CO. 4. Department of Radiology, University of Chicago, Chicago, IL. 5. Department of Radiology, University of Kentucky, Lexington, KY. 6. Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA. 7. Division of Rheumatology, Brigham and Women's Hospital, Boston, MA. 8. Division of Rheumatology, National Jewish Health, Denver, CO. 9. Interstitial Lung Disease Program & Autoimmune Lung Center, National Jewish Health, Denver, CO. 10. Inova Diagnostics, San Diego, CA. 11. Department of Pathology, National Jewish Health, Denver, CO. 12. Department of Pathology, National Jewish Health, Denver, CO; Department of Pathology, University of Colorado Denver, Aurora, CO.
Abstract
BACKGROUND: The etiology of idiopathic pulmonary fibrosis (IPF) is unknown. Because it shares genetic, histopathologic, and radiographic features with the fibrosing interstitial lung disease seen in rheumatoid arthritis (RA), the goal of this study was to investigate RA-related autoantibodies in IPF. METHODS: The study included patients with IPF from two separate cohorts at National Jewish Health and Brigham Women's Hospital (n = 181), general population control subjects (n = 160), and control subjects with disease (n = 86 [40 with RA-usual interstitial pneumonia and 46 with hypersensitivity pneumonitis]). Serum was tested for RA-associated antibodies (including IgG and IgA) to citrullinated protein antigens (ACPA). Lung tissue in 11 patients with IPF was examined for ectopic lymphoid aggregates. RESULTS: An increased prevalence of ACPA positivity was found in two separate IPF cohorts. In particular, positivity for IgA-ACPA was increased in these two IPF cohorts compared with general population control subjects (21.3% and 24.8% vs 5.6%; P < .01). Patients with IPF were more likely to be IgA-ACPA-positive than IgG-ACPA-positive (23.2% vs 8.3%; P < .01), whereas patients with RA were more likely to be IgG-ACPA-positive than IgA-ACPA-positive (72.5% vs 52.5%; P = .04). There was a strong correlation between IgA-ACPA level and the number of ectopic lymphoid aggregates on lung histologic examination in IPF (r = 0.72; P = .01). CONCLUSIONS: In this study, IgA-ACPA was elevated in patients with IPF and correlated with lymphoid aggregates in the lung, supporting the theory that IgA-ACPA may play a role in lung disease pathogenesis in a subset of individuals with IPF. Future studies are needed to determine whether this subset of ACPA-positive patients with IPF is distinct from patients with IPF but without antibodies.
BACKGROUND: The etiology of idiopathic pulmonary fibrosis (IPF) is unknown. Because it shares genetic, histopathologic, and radiographic features with the fibrosing interstitial lung disease seen in rheumatoid arthritis (RA), the goal of this study was to investigate RA-related autoantibodies in IPF. METHODS: The study included patients with IPF from two separate cohorts at National Jewish Health and Brigham Women's Hospital (n = 181), general population control subjects (n = 160), and control subjects with disease (n = 86 [40 with RA-usual interstitial pneumonia and 46 with hypersensitivity pneumonitis]). Serum was tested for RA-associated antibodies (including IgG and IgA) to citrullinated protein antigens (ACPA). Lung tissue in 11 patients with IPF was examined for ectopic lymphoid aggregates. RESULTS: An increased prevalence of ACPA positivity was found in two separate IPF cohorts. In particular, positivity for IgA-ACPA was increased in these two IPF cohorts compared with general population control subjects (21.3% and 24.8% vs 5.6%; P < .01). Patients with IPF were more likely to be IgA-ACPA-positive than IgG-ACPA-positive (23.2% vs 8.3%; P < .01), whereas patients with RA were more likely to be IgG-ACPA-positive than IgA-ACPA-positive (72.5% vs 52.5%; P = .04). There was a strong correlation between IgA-ACPA level and the number of ectopic lymphoid aggregates on lung histologic examination in IPF (r = 0.72; P = .01). CONCLUSIONS: In this study, IgA-ACPA was elevated in patients with IPF and correlated with lymphoid aggregates in the lung, supporting the theory that IgA-ACPA may play a role in lung disease pathogenesis in a subset of individuals with IPF. Future studies are needed to determine whether this subset of ACPA-positive patients with IPF is distinct from patients with IPF but without antibodies.
Authors: Javier Rangel-Moreno; Louise Hartson; Carmen Navarro; Miguel Gaxiola; Moises Selman; Troy D Randall Journal: J Clin Invest Date: 2006-12 Impact factor: 14.808
Authors: T Bongartz; T Cantaert; S R Atkins; P Harle; J L Myers; C Turesson; J H Ryu; D Baeten; E L Matteson Journal: Rheumatology (Oxford) Date: 2006-06-16 Impact factor: 7.580
Authors: Max A Seibold; Anastasia L Wise; Marcy C Speer; Mark P Steele; Kevin K Brown; James E Loyd; Tasha E Fingerlin; Weiming Zhang; Gunnar Gudmundsson; Steve D Groshong; Christopher M Evans; Stavros Garantziotis; Kenneth B Adler; Burton F Dickey; Roland M du Bois; Ivana V Yang; Aretha Herron; Dolly Kervitsky; Janet L Talbert; Cheryl Markin; Joungjoa Park; Anne L Crews; Susan H Slifer; Scott Auerbach; Michelle G Roy; Jia Lin; Corinne E Hennessy; Marvin I Schwarz; David A Schwartz Journal: N Engl J Med Date: 2011-04-21 Impact factor: 91.245
Authors: A Jimmy Ytterberg; Vijay Joshua; Gudrun Reynisdottir; Nataliya K Tarasova; Dorothea Rutishauser; Elena Ossipova; Aase Haj Hensvold; Anders Eklund; C Magnus Sköld; Johan Grunewald; Vivianne Malmström; Per Johan Jakobsson; Johan Rönnelid; Leonid Padyukov; Roman A Zubarev; Lars Klareskog; Anca I Catrina Journal: Ann Rheum Dis Date: 2014-05-09 Impact factor: 19.103
Authors: Solbritt Rantapää-Dahlqvist; Ben A W de Jong; Ewa Berglin; Göran Hallmans; Göran Wadell; Hans Stenlund; Ulf Sundin; Walther J van Venrooij Journal: Arthritis Rheum Date: 2003-10
Authors: Mary Y Armanios; Julian J-L Chen; Joy D Cogan; Jonathan K Alder; Roxann G Ingersoll; Cheryl Markin; William E Lawson; Mingyi Xie; Irma Vulto; John A Phillips; Peter M Lansdorp; Carol W Greider; James E Loyd Journal: N Engl J Med Date: 2007-03-29 Impact factor: 91.245
Authors: Joyce S Lee; Eunice J Kim; Kara L Lynch; Brett Elicker; Christopher J Ryerson; Tamiko R Katsumoto; Anthony K Shum; Paul J Wolters; Stefania Cerri; Luca Richeldi; Kirk D Jones; Talmadge E King; Harold R Collard Journal: Respir Med Date: 2012-11-24 Impact factor: 3.415
Authors: Joshua J Solomon; Jonathan H Chung; Gregory P Cosgrove; M Kristen Demoruelle; Evans R Fernandez-Perez; Aryeh Fischer; Stephen K Frankel; Stephen B Hobbs; Tristan J Huie; Jill Ketzer; Amar Mannina; Amy L Olson; Gloria Russell; Yutaka Tsuchiya; Zulma X Yunt; Pearlanne T Zelarney; Kevin K Brown; Jeffrey J Swigris Journal: Eur Respir J Date: 2015-11-19 Impact factor: 16.671
Authors: Ekaterina Klimatcheva; Tracy Pandina; Christine Reilly; Sebold Torno; Holm Bussler; Maria Scrivens; Alan Jonason; Crystal Mallow; Michael Doherty; Mark Paris; Ernest S Smith; Maurice Zauderer Journal: BMC Immunol Date: 2015-02-12 Impact factor: 3.615
Authors: Konstantin Tsoyi; Anthony J Esposito; Bo Sun; Ryan G Bowen; Kevin Xiong; Fernando Poli; Rafael Cardenas; Sarah G Chu; Xiaoliang Liang; Stefan W Ryter; Christine Beeton; Tracy J Doyle; Matthew J Robertson; Lindsay J Celada; Freddy Romero; Souheil Y El-Chemaly; Mark A Perrella; I-Cheng Ho; Ivan O Rosas Journal: Sci Rep Date: 2022-02-18 Impact factor: 4.996